Dan Lundstedt

2.1k total citations · 1 hit paper
30 papers, 1.1k citations indexed

About

Dan Lundstedt is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Dan Lundstedt has authored 30 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Cancer Research, 14 papers in Oncology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Dan Lundstedt's work include Breast Cancer Treatment Studies (24 papers), Breast Lesions and Carcinomas (8 papers) and Advanced Radiotherapy Techniques (8 papers). Dan Lundstedt is often cited by papers focused on Breast Cancer Treatment Studies (24 papers), Breast Lesions and Carcinomas (8 papers) and Advanced Radiotherapy Techniques (8 papers). Dan Lundstedt collaborates with scholars based in Sweden, Denmark and Italy. Dan Lundstedt's co-authors include Per Karlsson, Erik Holmberg, Birgitte Vrou Offersen, Á. Montero, Jean‐Philippe Pignol, Karolien Verhoeven, Carine Kirkove, Youlia Kirova, Liesbeth Boersma and Marianne Aznar and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Dan Lundstedt

29 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer

2015 485 citations Birgitte Vrou Offersen, Liesbeth Boersma et al. Radiotherapy and Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dan Lundstedt Sweden	14	739	416	336	285	274	30	1.1k
Brian Magee United Kingdom	7	792 1.1×	400 1.0×	371 1.1×	243 0.9×	288 1.1×	9	1.2k
JA Dewar United Kingdom	3	817 1.1×	401 1.0×	382 1.1×	203 0.7×	316 1.2×	6	1.0k
A.M. Moody United Kingdom	15	648 0.9×	229 0.6×	405 1.2×	238 0.8×	190 0.7×	26	995
Kathy Baglan United States	11	680 0.9×	269 0.6×	586 1.7×	391 1.4×	303 1.1×	15	1.1k
Boon Chua Australia	21	934 1.3×	486 1.2×	135 0.4×	357 1.3×	555 2.0×	57	1.2k
Hosam A. Kader Canada	15	730 1.0×	268 0.6×	229 0.7×	371 1.3×	471 1.7×	20	965
Luis Sanchez Italy	18	698 0.9×	360 0.9×	269 0.8×	469 1.6×	342 1.2×	43	1.2k
Heidi Stranzl Austria	14	536 0.7×	513 1.2×	161 0.5×	264 0.9×	240 0.9×	29	1.1k
Conny Vrieling Netherlands	12	795 1.1×	313 0.8×	176 0.5×	549 1.9×	389 1.4×	21	1.1k
Yarnold United Kingdom	2	803 1.1×	366 0.9×	381 1.1×	203 0.7×	316 1.2×	3	986

Countries citing papers authored by Dan Lundstedt

Since Specialization

Citations

This map shows the geographic impact of Dan Lundstedt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Lundstedt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Lundstedt more than expected).

Fields of papers citing papers by Dan Lundstedt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan Lundstedt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Lundstedt. The network helps show where Dan Lundstedt may publish in the future.

Co-authorship network of co-authors of Dan Lundstedt

This figure shows the co-authorship network connecting the top 25 collaborators of Dan Lundstedt. A scholar is included among the top collaborators of Dan Lundstedt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dan Lundstedt. Dan Lundstedt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boniface, Jana de, Tove Filtenborg Tvedskov, Jan Frisell, et al.. (2024). Abstract GS02-06: Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial. Cancer Research. 84(9_Supplement). GS02–6.

Appelgren, Matilda, Robert Szulkin, Sara Alkner, et al.. (2024). Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial. The Lancet Oncology. 25(9). 1222–1230. 9 indexed citations

Alkner, Sara, Dan Lundstedt, Martin Berg, et al.. (2024). Quality assessment of radiotherapy in the prospective randomized SENOMAC trial. Radiotherapy and Oncology. 197. 110372–110372. 4 indexed citations

Tvedskov, Tove Filtenborg, Robert Szulkin, Sara Alkner, et al.. (2024). Axillary clearance and chemotherapy rates in ER+HER2− breast cancer: secondary analysis of the SENOMAC trial. The Lancet Regional Health - Europe. 47. 101083–101083. 1 indexed citations

Alkner, Sara, Jana de Boniface, Dan Lundstedt, et al.. (2023). Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases – an open, multicentre, randomised non-inferiority phase 3 trial. BMJ Open. 13(9). e075543–e075543. 7 indexed citations

Sjöström, Martin, Emma Niméus, Fredrika Killander, et al.. (2023). Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial. Clinical Cancer Research. 29(9). 1783–1793. 2 indexed citations

Linderholm, Barbro, Antonios Valachis, Vidar G. Flote, et al.. (2023). 259TiP Treatment of oligometastatic breast cancer (OMBC): A randomised phase III trial comparing stereotactic ablative radiotherapy (SABR) and systemic treatment with systemic treatment alone as first-line treatment - TAORMINA. ESMO Open. 8(1). 101447–101447. 2 indexed citations

Puttonen, Henri, Martin Sjöström, Erik Holmberg, et al.. (2020). Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial. Clinical Cancer Research. 27(3). 749–758. 17 indexed citations

Killander, Fredrika, Elinore Wieslander, Per Karlsson, et al.. (2020). No Increased Cardiac Mortality or Morbidity of Radiation Therapy in Breast Cancer Patients After Breast-Conserving Surgery: 20-Year Follow-up of the Randomized SweBCGRT Trial. International Journal of Radiation Oncology*Biology*Physics. 107(4). 701–709. 16 indexed citations

10.

Boniface, Jana de, Johan Ahlgren, Yvette Andersson, et al.. (2020). The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer. Breast Cancer Research and Treatment. 180(1). 167–176. 10 indexed citations

11.

Lundstedt, Dan, Fredrika Killander, Erik Holmberg, et al.. (2019). Distribution of Locoregional Breast Cancer Recurrence in Relation to Postoperative Radiation Fields and Biological Subtypes. International Journal of Radiation Oncology*Biology*Physics. 105(2). 285–295. 11 indexed citations

12.

Svensson, Henrik, et al.. (2019). Integration of biological factors in the treatment plan evaluation in breast cancer radiotherapy. Physics and Imaging in Radiation Oncology. 11. 54–60. 2 indexed citations

13.

Lundstedt, Dan, et al.. (2018). Positive sentinel node in luminal A-like breast cancer patients - implications for adjuvant chemotherapy?. Acta Oncologica. 58(2). 162–167. 8 indexed citations

14.

Boniface, Jana de, Jan Frisell, Yvette Andersson, et al.. (2017). Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer. 17(1). 379–379. 106 indexed citations

15.

Killander, Fredrika, Per Karlsson, H. Anderson, et al.. (2016). No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT. European Journal of Cancer. 67. 57–65. 48 indexed citations

16.

Lundstedt, Dan, Magnus Gustafsson, Gunnar Steineck, et al.. (2015). Radiation Therapy to the Plexus Brachialis in Breast Cancer Patients: Analysis of Paresthesia in Relation to Dose and Volume. International Journal of Radiation Oncology*Biology*Physics. 92(2). 277–283. 13 indexed citations

17.

Offersen, Birgitte Vrou, Liesbeth Boersma, Carine Kirkove, et al.. (2015). ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiotherapy and Oncology. 114(1). 3–10. 485 indexed citations breakdown →

18.

Alsadius, David, Maria Hedelin, Dan Lundstedt, et al.. (2012). Mean Absorbed Dose to the Anal-Sphincter Region and Fecal Leakage among Irradiated Prostate Cancer Survivors. International Journal of Radiation Oncology*Biology*Physics. 84(2). e181–e185. 21 indexed citations

19.

Lundstedt, Dan, Magnus Gustafsson, Gunnar Steineck, et al.. (2011). Risk Factors of Developing Long-Lasting Breast Pain After Breast Cancer Radiotherapy. International Journal of Radiation Oncology*Biology*Physics. 83(1). 71–78. 35 indexed citations

20.

Lundstedt, Dan, Magnus Gustafsson, Per Malmström, et al.. (2010). Symptoms 10–17 years after breast cancer radiotherapy data from the randomised SWEBCG91-RT trial. Radiotherapy and Oncology. 97(2). 281–287. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact